Target‐Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities

Clinical trials can fail to detect rare adverse events (AEs). We assessed the ability of pharmacological target adverse‐event (TAE) profiles to predict AEs on US Food and Drug Administration (FDA) drug labels at least 4 years after approval. TAE profiles were generated by aggregating AEs from the FDA adverse event reporting system (FAERS) reports and the FDA drug labels for drugs that hit a common target. A genetic algorithm (GA) was used to choose the adverse event (AE) case count (N), disproportionality score in FAERS (proportional reporting ratio (PRR)), and percent of comparator drug labels with an AE to maximize F‐measure. With FAERS data alone, precision, recall, and specificity were 0.57, 0.78, and 0.61, respectively. After including FDA drug label data, precision, recall, and specificity improved to 0.67, 0.81, and 0.71, respectively. Eighteen of 23 (78%) postmarket label changes were identified correctly. TAE analysis shows promise as a method to predict AEs at the time of drug approval.

[1]  Alexander Zien,et al.  Improving drug safety with a systems pharmacology approach. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[3]  Wei-Yin Loh,et al.  Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..

[4]  Rebecca Racz,et al.  Association Between Serotonin Syndrome and Second‐Generation Antipsychotics via Pharmacological Target‐Adverse Event Analysis , 2018, Clinical and translational science.

[5]  Hua Xu,et al.  Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs , 2012, J. Am. Medical Informatics Assoc..

[6]  K. Sonawane,et al.  Serious adverse Drug events reported to the Food and Drug Administration (FDA): analysis of the FDA adverse event reporting system (FAERS) 2006-2011 database , 2015 .

[7]  Darrell R Abernethy,et al.  Systems pharmacology to predict drug toxicity: integration across levels of biological organization. , 2013, Annual review of pharmacology and toxicology.

[8]  D R Abernethy,et al.  Integration of Diverse Data Sources for Prediction of Adverse Drug Events , 2011, Clinical pharmacology and therapeutics.

[9]  Jie Shen,et al.  Adverse Drug Events: Database Construction and in Silico Prediction , 2013, J. Chem. Inf. Model..

[10]  R. Sharan,et al.  Metabolic Network Prediction of Drug Side Effects. , 2016, Cell systems.

[11]  P. Bork,et al.  Systematic identification of proteins that elicit drug side effects , 2013, Molecular systems biology.

[12]  Ram C Tiwari,et al.  Likelihood Ratio Test-Based Method for Signal Detection in Drug Classes Using FDA's AERS Database , 2013, Journal of biopharmaceutical statistics.

[13]  Salma Jamal,et al.  Predicting neurological Adverse Drug Reactions based on biological, chemical and phenotypic properties of drugs using machine learning models , 2017, Scientific Reports.

[14]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[15]  Avi Ma'ayan,et al.  Drug-induced adverse events prediction with the LINCS L1000 data , 2016, Bioinform..

[16]  Patrick B. Ryan,et al.  Accuracy of an automated knowledge base for identifying drug adverse reactions , 2017, J. Biomed. Informatics.

[17]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[18]  Abdul Mateen Rajput,et al.  Automatic detection of adverse events to predict drug label changes using text and data mining techniques , 2013, Pharmacoepidemiology and drug safety.

[19]  Luca Scrucca,et al.  GA: A Package for Genetic Algorithms in R , 2013 .

[20]  Harlan M. Krumholz,et al.  Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010 , 2017, JAMA.

[21]  Rong Xu,et al.  Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS) , 2014, J. Biomed. Informatics.

[22]  正博 頭金.  FDA adverse event reporting system (FAERS) , 2015 .

[23]  Ich Harmonised,et al.  INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE , 2006 .

[24]  J. Chen,et al.  Predicting adverse side effects of drugs , 2011, BMC Genomics.